SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases
- Written by ACN Newswire
HONG KONG, Sep 17, 2021 - (ACN Newswire) - SinoMab BioScience Limited (HKEX 3681.HK, "SinoMab") announced with Suzhou Sinovent Pharmaceuticals Co., Ltd. ("Sinovent") today that they have entered into an exclusive licensing agreement with Everest Medicines (HKEX 1952.HK, "Everest") to out-license the right to develop and commercialize SN1011...